When President Kennedy’s newborn son died in 1963, it galvanized research. A new Kennedy family tragedy should spur RFK Jr. to support cancer research, not cut it.

Vaccines do not cause autism. You’ve almost certainly read that before — but often without a full explanation of how we know it to be true. Here's how we know.

Jesús (Tito) González, Paul A. Negulescu, Michael J. Welsh

Glucagon-like peptide 1 receptor (GLP-1R) agonists exhibit anti-inflammatory actions, yet the importance of direct immune cell GLP-1R signaling remains uncertain. Although T cells respond to GLP-1, lo...

What happened when a public health scientist overheard four men sharing misinformation about Covid — and decided to talk to them about it.

Scientific research is at the heart of Israel’s success and has worldwide benefits. Our work will continue despite adversity.

The custom-built gene editing treatment for 6-month-old KJ Muldoon could not have come at a more welcome or jarring time for CRISPR-powered biomedicine.

The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the FDA by the Trump administration may ...

Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69%...

A small Oakland, CA-based biotech hoping to take on the sprawling landscape of substance use disorders and addiction has reeled in $70 million. The drug development startup, named Tempero Bio ...

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across I...

At least 124 cases have been reported since late January, mostly among children and teenagers who were unvaccinated or whose vaccination status was unknown.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary p...

Earlier this month, the National Institutes of Health issued supplemental guidance indicating it would immediately impose a 15% cap on indirect costs for research grants, an unprecedented and abrup…

Epigenetic editing of PCSK9 in the liver, designed to induce DNA methylation and silence gene expression, achieved long-lasting reductions in LDL cholesterol levels in both transgenic mice expressing ...

Epigenetic editing of PCSK9 in the liver, designed to induce DNA methylation and silence gene expression, achieved long-lasting reductions in LDL cholesterol levels in both transgenic mice expressing ...

Epicardial engineered heart muscle allografts from induced pluripotent stem cell-derived cardiomyocytes can safely and effectively remuscularize chronically failing hearts in rhesus macaques, leading ...

Curie.Bio, the biotech accelerator and investment firm, has raised another $340 million to invest in startups.

SAN FRANCISCO — Ben Auspitz, a veteran biotech investor and repeat entrepreneur, is reuniting with longtime collaborator Alexis Borisy and his

Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-bas

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstr...

More than 100 clinical trials put stem cells for regenerative medicine to the test. It’s a turning point for a field beset with ethical and political controversy.

Over the years, a handful of cities have tried catching up to the flourishing biotech hubs in Boston or the San Francisco Bay Area. Chicago, the third-largest city in the US, is putting together its b...

In industry parlance, the deal joins a “delivery” company with a “cargo” company — fusing the two key pieces needed to build a genetic medicine.

Curie.Bio is a new model for venture capital in biotech. We are focused on a singular mission – helping founders launch therapeutics companies that go on to raise an awesome next round of financing.

Study published in Science says a single hemagglutinin mutation, similar to one seen in a Canadian case, could make H5N1 better suited to infect people.

Roche's Genentech will work with a Chicago-area biotech to create nanoparticle treatments for an undisclosed autoimmune disease, the companies said Tuesday morning. Genentech is paying $40 million in ...

There's growing interest in radiopharmaceuticals. But a "significant talent shortage" may threaten the field's rise.

Genetic investigation of a cardiac arrhythmia reveals a new noncoding Mendelian disease mechanism